Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma

► Current therapies for advanced adrenocortical cancer are insufficient. ► The dual PI3K/mTOR inhibitor NVP-BEZ235 efficiently inhibits ACC cell proliferation. ► Concomitant inhibition of Erk may be required to potentiate the NVP-BEZ235 effect.